CTSO vs. NNOX, ZIMV, SNWV, CATX, NYXH, DRTS, SMTI, BWAY, SKIN, and TCMD
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include Nano-X Imaging (NNOX), ZimVie (ZIMV), Sanuwave Health (SNWV), Perspective Therapeutics (CATX), Nyxoah (NYXH), Alpha Tau Medical (DRTS), Sanara MedTech (SMTI), Brainsway (BWAY), Beauty Health (SKIN), and Tactile Systems Technology (TCMD). These companies are all part of the "medical equipment" industry.
Cytosorbents vs. Its Competitors
Cytosorbents (NASDAQ:CTSO) and Nano-X Imaging (NASDAQ:NNOX) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.
32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Cytosorbents had 5 more articles in the media than Nano-X Imaging. MarketBeat recorded 5 mentions for Cytosorbents and 0 mentions for Nano-X Imaging. Nano-X Imaging's average media sentiment score of 0.00 beat Cytosorbents' score of -0.19 indicating that Nano-X Imaging is being referred to more favorably in the news media.
Cytosorbents has higher revenue and earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
Cytosorbents currently has a consensus price target of $5.50, indicating a potential upside of 423.81%. Nano-X Imaging has a consensus price target of $9.50, indicating a potential upside of 81.64%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Nano-X Imaging.
Cytosorbents has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Nano-X Imaging has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500.
Cytosorbents has a net margin of -41.77% compared to Nano-X Imaging's net margin of -472.19%. Nano-X Imaging's return on equity of -30.92% beat Cytosorbents' return on equity.
Summary
Cytosorbents beats Nano-X Imaging on 10 of the 16 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
This page (NASDAQ:CTSO) was last updated on 7/9/2025 by MarketBeat.com Staff
